USPTO serial 86058412
AGMAX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- COLEMAN, CIMMERIAN
- Law office
- TMEG LAW OFFICE 102 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with AGMAX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Albumin dietary supplements; Alginate dietary supplements; Alkalinity buffer supplements for live coral for use in aquariums; Animal feed additive for use as a nutritional supplement for medical purposes; Animal feed supplements; Antioxidant enriched coffee; Bee pollen for use as a dietary food supplement; Beverages containing chlorophyll for use as a nutritional supplement; Calcium montmorillonite clay for therapeutic purposes used to enhance the production of enzymes in living beings or as a mineral supplement; Calcium supplements; Calcium-based nutrient supplements for live coral for use in aquariums; Casein dietary supplements; Dietary and nutritional supplements; Dietary and nutritional supplements for endurance sports; Dietary and nutritional supplements used for weight loss; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Enzyme food supplements; Flaxseed dietary supplements; Flaxseed oil dietary supplements; Food supplements; Glucose dietary supplements; Ground flaxseed fiber for use as a dietary supplement; Health food supplements; Herbal supplements; Herbal supplements for sleeping problems; Homeopathic supplements; Human allograft bone and tissue; Human allograft tissue; Human growth hormone; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Lecithin for use as a dietary supplement; Linseed dietary supplements; Linseed oil dietary supplements; Liquid herbal supplements; Liquid nutritional supplement; Liquid protein supplements; Medical adhesive tape; Medical adhesives for binding internal tissue; Medical adhesives for binding wounds; Medical and surgical dressings; Medical and surgical plasters; Medical cleansers for skin and wounds; Medical diagnostic reagents; Medical diagnostic reagents and assays for testing body fluids for microorganisms; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Medical dressings; Medical lubricant, namely, vaginal lubricants; Medical plasters; Medical preparations for slimming purposes; Medical preparations, namely, foot, hand and skin creams for diabetics; Medicinal alcohol; Medicinal creams for skin care; Medicinal drinks; Medicinal hair growth preparations; Medicinal herb extracts; Medicinal herbal extracts for medical purposes; Medicinal herbal preparations; Medicinal herbs; Medicinal herbs in dried or preserved form; Medicinal oils; Medicinal preparations for stimulating hair growth; Medicinal preparations for the mouth and as sprays; Medicinal preparations for the mouth to be applied in the form of drops, capsules, tablets and compressed tablets; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal radix glycyrrhizae; Medicinal roots; Medicinal tea; Medicines for dental purposes; Medicines for the treatment of gastrointestinal diseases; Mineral nutritional supplements; Non-medicated additives for animal feed for use as nutritional supplements; Nopal cactus juice for use as a nutritional supplement; Nutritional and dietary supplements formed and packaged as bars; Nutritional drinks for animals; Nutritional meal replacement bars adapted for medical use for individuals undergoing medical treatments; Nutritional supplement energy bars; Nutritional supplement for eliminating toxins from the body; Nutritional supplement for eliminating toxins from the intestinal tract; Nutritional supplement in the nature of a nutrient-dense, protein-based drink mix; Nutritional supplement meal replacement bars for boosting energy; Nutritional supplement shakes; Nutritional supplements; Nutritional supplements in capsule form for dogs; Nutritional supplements in lotion form sold as a component of nutritional skin care products; Nutritional supplements in the nature of nutritionally fortified soft chews; Nutritional supplements, namely, carbohydrates in powdered form; Nutritional supplements, namely, probiotic compositions; Nutritive substances for micro-organisms for medical use; Nutritive substances for microorganism cultures; Nutritive substances for microorganisms for medical purposes; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical antitussive-cold preparations; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for reducing sexual activity; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, dantrolene sodium for injection; Pharmaceutical preparations, namely, injectable contraceptives; Powdered nutritional supplement concentrate; Powdered nutritional supplement drink mix; Powdered nutritional supplement drink mix and concentrate; Soy protein for use as a nutritional supplement in various powdered and ready-to-drink beverages; Vegan protein for use as a nutritional supplement in ready-to-drink beverages; Veterinary preparations, namely, antioxidants | ACTIVE | Aug 8, 2008 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 16, 2014 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jul 16, 2014 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Dec 18, 2013 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2013 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 18, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 16, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 11, 2013 | NWAP | NEW APPLICATION ENTERED | — |